Identification of Metabolites of NK-104,an HMG-CoA Reductase Inhibitor, in Rat, Rabbit and Dog Bile
スポンサーリンク
概要
- 論文の詳細を見る
NK-104 is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase with a very potent lipid-lowering effect. Biotransformation profiles of NK-104 in bile from rat, rabbit and dog given an intravenous infusion of NK-104 were investigated. Structural assignment was made by liquid chromatography (LC)-mass spectrometry (MS)-MS and proton NMR analyses. The predominant component was intact NK-104 in all the animals. At least eight other metabolites were present in rat, four in rabbit, and 10 in dog. These bile metabolites were purified and isolated by preparative HPLC. Biotransformation pathways elucidated for NK-104 were as follows : (a) lactonization ; (b) β-oxidation of the side-chain; (c) hydroxylation of the quinoline ring; (d) conjugation with β-glucuronic acid and taurine. β-oxidative degradation of the side-chain in the case of other HMG-CoA reductase inhibitors is necessary for epimerization of the hydroxy group which has an R-configuration. However, M-16,glucuronide of the ketolactone derivative, was obtained as a key metabolite suggesting another β-oxidation pathway for the side-chain.
- 公益社団法人日本薬学会の論文
- 1999-02-15
著者
-
KANDA Hiroyasu
日産化学工業株式会社中央研究所
-
KIMATA Hideki
興和株式会社東京研究所
-
Kimata H
Kowa Company Ltd. Tokyo
-
Kojima Juniji
興和株式会社東京研究所
-
Kojima Junji
Tokyo New Drug Research Laboratories Kowa Company Ltd.
-
Kojima Junji
Ntt Human Interface Laboratories
-
Fujino Hideki
Tokyo New Drug Research Laboratories Kowa Company Ltd.
-
KIMATA Hideki
Tokyo Research Laboratories, Kowa Co., Ltd.
-
YOSIMURA Mitsuo
Tokyo Research Laboratories, Kowa Company Ltd.
-
KOJIMA Juniji
Tokyo Research Laboratories, Kowa Co., Ltd.,
-
ABE Haruyasu
Tokyo Research Laboratories, Kowa Co., Ltd.,
-
KANDA Hiroyasu
Central Research Institute, Nissan Chemical Industries, Ltd.,
-
Abe Haruyasu
Tokyo Research Laboratories Kowa Co. Ltd.
-
Yosimura Mitsuo
Tokyo Research Laboratories Kowa Company Ltd.
-
Kimata Hideki
Tokyo Research Laboratories, Kowa Co. Ltd.
関連論文
- Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (4) : Interspecies Variation in Laboratory Animals and Humans
- Importance of Sialic Acid in Recombinant Thrombomodulin in Terms of Pharmacokinetics and Separation of Desialyzed Glycoprotein
- Binding of Human Tissue Plasminogen Activator (t-PA) to Blood Clots and Clot-Lytic Activity of Clot-Bound t-PA
- Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs
- Uptake Mechanism of Pitavastatin, a New Inhibitor of HMG-CoA Reductase, in Rat Hepatocytes
- Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase : Effect of cMOAT Deficiency on Hepatobiliary Excretion in Rats and of mdr1a/b Gene Disruption on Tissue Distribution in Mice
- Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reduetase (5) : In Vitro Metabolism and Plasma Protein Binding in Animals and Human
- Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection
- Identification of Metabolites of NK-104,an HMG-CoA Reductase Inhibitor, in Rat, Rabbit and Dog Bile
- A Fast Projection Algorithm for Adaptive Filtering
- Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (2) : Absorption, Distribution, Metabolism, Excretion and Accumulation Following Repeated Oral Administration of ^C-NK-104 in Rats
- Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (1) : Absorption, Distribution, Metabolism and Excretion in Rats
- Thrombolytic Effect of Tissue Plasminogen Activator in a Cerebral Embolic Model
- Localization of Tissue Plasminogen Activator on Experimental Microthrombi in Rats. Microautoradiographic Observations
- Localization of Tissue Plasminogen Activator on Experimental Thrombi in Rats
- PHARMACOKINETICS OF NIPRADILOL (K-351), A NEW ANTIHYPERTENSIVE AGENT. I. STUDIES ON INTERSPECIES VARIATION IN LABORATORY ANIMALS
- PHARMACOKINETICS OF NIPRADILOL (K-351), A NEW ANTIHYPERTENSIVE AGENT. II. INFLUENCE OF THE ROUTE OF ADMINISTRATION ON BIOAVAILABILITY IN DOGS
- Studies on metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase-Does glucronidation mediate the lactonization of pitavastatin?
- Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay-inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase
- Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (3) : Foeto-placental Transfer and Mammary Excretion after Oral Administration in Rats
- Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent, in human.
- Possibility of the Low Defensive Fibrinolysis in SHRSP